Dawei Wang

2.2k total citations · 1 hit paper
95 papers, 1.3k citations indexed

About

Dawei Wang is a scholar working on Molecular Biology, Epidemiology and Oncology. According to data from OpenAlex, Dawei Wang has authored 95 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 20 papers in Epidemiology and 18 papers in Oncology. Recurrent topics in Dawei Wang's work include Kidney Stones and Urolithiasis Treatments (8 papers), Virus-based gene therapy research (7 papers) and CAR-T cell therapy research (6 papers). Dawei Wang is often cited by papers focused on Kidney Stones and Urolithiasis Treatments (8 papers), Virus-based gene therapy research (7 papers) and CAR-T cell therapy research (6 papers). Dawei Wang collaborates with scholars based in China, United States and Australia. Dawei Wang's co-authors include Yuan Shao, Guo‐Liang Lu, Yujia Cai, Jiaxu Hong, Sikai Ling, Søren R. Paludan, Di Yin, Yao Dai, Da Xu and Hao Jiang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nature Biotechnology.

In The Last Decade

Dawei Wang

89 papers receiving 1.3k citations

Hit Papers

Targeting herpes simplex virus with CRISPR–Cas9 cures her... 2021 2026 2022 2024 2021 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice
    2021 122 citations Di Yin, Sikai Ling et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dawei Wang China 20 762 220 205 182 181 95 1.3k
Zheng Hu China 24 1.1k 1.4× 273 1.2× 213 1.0× 319 1.8× 161 0.9× 83 1.7k
Weiping Wang China 21 951 1.2× 158 0.7× 92 0.4× 137 0.8× 213 1.2× 68 1.5k
Bei Cai China 24 644 0.8× 365 1.7× 368 1.8× 199 1.1× 338 1.9× 89 1.7k
Bongkun Choi South Korea 22 531 0.7× 196 0.9× 83 0.4× 233 1.3× 346 1.9× 43 1.2k
Mitra Esfandiarei Canada 17 617 0.8× 256 1.2× 325 1.6× 136 0.7× 389 2.1× 48 1.7k
Shuai He China 21 861 1.1× 118 0.5× 87 0.4× 176 1.0× 165 0.9× 69 1.4k
Latha P. Ganesan United States 24 712 0.9× 247 1.1× 140 0.7× 152 0.8× 642 3.5× 42 1.7k
Yuan Chao Xue Canada 21 1.3k 1.7× 191 0.9× 191 0.9× 139 0.8× 161 0.9× 41 1.9k

Countries citing papers authored by Dawei Wang

Since Specialization
Citations

This map shows the geographic impact of Dawei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawei Wang more than expected).

Fields of papers citing papers by Dawei Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawei Wang. The network helps show where Dawei Wang may publish in the future.

Co-authorship network of co-authors of Dawei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Dawei Wang. A scholar is included among the top collaborators of Dawei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawei Wang. Dawei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Yanyu, Sulan Luo, Shujing Lin, et al.. (2025). Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction. International Journal of Molecular Sciences. 26(19). 9669–9669.
2.
3.
Gao, Xinjie, et al.. (2025). C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China. Blood Advances. 9(8). 1836–1846. 1 indexed citations
4.
Hao, Kexin, Yi-Meng Li, Ling Wang, et al.. (2024). Composition of four polyphenol fractions extracted from partridge tea and their mechanisms on ameliorate insulin resistance in HepG2 cells. Food Bioscience. 62. 105380–105380. 3 indexed citations
5.
6.
Wang, Yihan, et al.. (2024). Costunolide Inhibits Chronic Kidney Disease Development by Attenuating IKKβ/NF-κB Pathway. Drug Design Development and Therapy. Volume 18. 2693–2712.
7.
Wang, Dawei, et al.. (2023). TRIM29 knockdown prevented the colon cancer progression through decreasing the ubiquitination levels of KRT5. Open Life Sciences. 18(1). 20220711–20220711. 6 indexed citations
8.
Wang, Dawei, et al.. (2023). Metabolomics in viral hepatitis: advances and review. Frontiers in Cellular and Infection Microbiology. 13. 1189417–1189417. 12 indexed citations
9.
Bai, Kunhao, et al.. (2022). Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint. Computational and Structural Biotechnology Journal. 20. 5226–5234. 15 indexed citations
10.
Wang, Dawei, Aina Liu, Tianqi Wang, et al.. (2022). Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience. Frontiers in Pharmacology. 13. 837499–837499. 3 indexed citations
11.
Wang, Dawei, Qiang Wang, Xiaohong Pan, et al.. (2021). Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. SHILAP Revista de lepidopterología. 11(3). e375–e375. 3 indexed citations
12.
Yin, Di, Sikai Ling, Dawei Wang, et al.. (2021). Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice. Nature Biotechnology. 39(5). 567–577. 122 indexed citations breakdown →
13.
Ling, Sikai, Shiqi Yang, Xinde Hu, et al.. (2021). Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nature Biomedical Engineering. 5(2). 144–156. 135 indexed citations
14.
Liu, Jiayu, et al.. (2021). Treatment of a Hemophilia B Mouse Model with Platelet-Targeted Expression of Factor IX Padua. Human Gene Therapy. 32(9-10). 506–516. 1 indexed citations
15.
Wang, Dawei, et al.. (2020). IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model. Journal of Translational Medicine. 18(1). 23–23. 49 indexed citations
16.
Lu, Guo‐Liang, et al.. (2020). Factors Influencing Surgical Outcome in Retrograde Management of Parapelvic Renal Cysts. Journal of Endourology. 35(4). 466–472. 3 indexed citations
17.
Wang, Dawei, et al.. (2020). Using postmortem formalin fixed paraffin-embedded tissues for molecular testing of sudden cardiac death: A cautionary tale of utility and limitations. Forensic Science International. 308. 110177–110177. 9 indexed citations
18.
Li, Wei, et al.. (2019). Sinonasal/nasopharyngeal pleomorphic adenoma and carcinoma ex pleomorphic adenoma: a report of 17 surgical cases combined with a literature review. SHILAP Revista de lepidopterología. 2 indexed citations
19.
Peng, Yunru, et al.. (2010). Oral pharmacokinetics of caudatin in rats.. Chinese Journal of Natural Medicines. 8(6). 471–473. 3 indexed citations
20.
Yao, Nan, et al.. (2008). [Determination of paeoniflorin in rat plasma by HPLC-MS/MS and its pharmacokinetics].. PubMed. 33(20). 2369–73. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zheng Hu Breakdown of academic impact, for papers by Weiping Wang Breakdown of academic impact, for papers by Bei Cai Breakdown of academic impact, for papers by Bongkun Choi Breakdown of academic impact, for papers by Mitra Esfandiarei Breakdown of academic impact, for papers by Shuai He Breakdown of academic impact, for papers by Latha P. Ganesan Breakdown of academic impact, for papers by Yuan Chao Xue
Rankless by CCL
2026